恩度联合吉西他滨、多西他赛治疗晚期软组织肉瘤的疗效及安全性

Efficacy and safety of endostar combined with gemcitabine and docetaxel in advanced soft tissue sarcomas

目的:探讨恩度联合吉西他滨、多西他赛(GD)治疗晚期软组织肉瘤的疗效及安全性。方法:选取2013年1月至2016年4月入住我院晚期软组织肉瘤患者49例,随机分为恩度组(恩度联合吉西他滨、多西他赛)和对照组(吉西他滨联合多西他赛),比较两组患者疾病控制率、客观缓解率、不良反应及无进展生存期。结果:恩度组疾病控制率为52.17%,高于对照组的23.08%,经χ2检验差异有统计学意义(P<0.05);两组客观缓解率分别为17.39%和3.85%,差异无统计学意义(P>0.05);两组患者Ⅲ、Ⅳ度不良反应差异均无统计学意义(P>0.05)。恩度组无进展生存期为(4.08±0.70)月,对照组为(2.35±0.29)月,差异有统计学意义(P<0.05)。结论:恩度联合GD方案对晚期软组织肉瘤疗效较GD方案好,患者耐受性好,可考虑应用于晚期软组织肉瘤患者。

Objective：To investigate the efficacy and safety of endostar combined with gemcitabine and docetaxel（GD） in advanced soft tissue sarcomas. Methods ：49 patients with advanced soft tissue sarcomas from January 2013 to April 2016 in our hospital were randomly divided into endostar group （endostar combined with gemcitabine and do-cetaxel） and control group （gemcitabine combined with docetaxel）. Two groups of patients^disease control rates,ob-jective response rates,adverse reaction and progression - free survival were compared. Results： In endostar group and the control group,disease control rates were 52. 17% and 23. 08% respectively （P 〈 0. 05 ） and objective response rates were 17. 39% and 3. 85% respectively （P 〉0. 05）. There was no statistically significant difference between two groups of patients with grade HI and IV adverse reactions. Progression - free survial was （4. 08 ± 0. 70） months and （2.35 ±0.29） months in endostar group and control group , and the difference was statistically significant （ P 〈0.05）. Conclusion：Endostar combined GD regimen has better curative effect than GD regimen,and has good toler-ance in advanced soft tissue sarcomas.